论文部分内容阅读
本文用放射免疫方法检测35例DCM患者PRA-AT I-ALD系统(RAAS)浓度,并与33例健康人作对照,还对其中16例患者进行了治疗前后的观察,结果为:DCM患者血浆RAA浓度明显高于健康对照组(P<0.001);并发心律失常者PRA浓度明显高于无并发心律失常者(P<0.05);同时并发心律失常和心衰者RAA浓度明显高于单纯并发心律失常者(P<0.05);DCM患者血浆PRA,ATI,ALD浓度增高具有一致性;DCM患者治疗后RAA浓度明显降低(P<0.05～0.001)。提示:RAAS参与DCM的发生和发展,DCM患者血浆RAA浓度增高,且与心功能不全程度有关.因此,动态观察DCM患者血浆RAA浓度变化,对判断病情程度、监测心衰的发生与发展、制定治疗方案、估价疗效和预后均有重要的临床实用价值。
PRA-AT I-ALD system (RAAS) was detected by radioimmunoassay in 35 patients with DCM and compared with 33 healthy individuals. 16 patients were also observed before and after treatment. The results were as follows: (P <0.001). The concentration of PRA in patients with arrhythmia was significantly higher than that in patients without concomitant arrhythmia (P0.05). The concentration of RAA in patients with concurrent arrhythmia and heart failure was significantly higher than that in patients with simple heart beat (P <0.05). The plasma concentrations of PRA, ATI and ALD in patients with DCM were consistent. The concentrations of RAA in patients with DCM were significantly lower (P <0.05-0.001). It is concluded that RAAS participates in the occurrence and development of DCM, and the concentration of plasma RAA is increased in patients with DCM, which is related to the degree of cardiac insufficiency.Therefore, the dynamic changes of plasma RAA concentration in patients with DCM are analyzed to determine the severity of disease and monitor the occurrence and development of heart failure. Treatment options, evaluation of the efficacy and prognosis have important clinical value.